Abstract
Purpose of reviewRobotic-assisted laparoscopic retroperitoneal lymph node dissection (R-RPLND) is gaining acceptance as an alternative to open and laparoscopic RPLND for the treatment of testicular cancer. We discuss the current state of R-RPLND and summarize the latest relevant literature regarding the feasibility of this operation.Recent findingsR-RPLND has been utilized effectively for both treatment of high-risk, clinical stage I testicular cancer as well as in the postchemotherapy setting. The feasibility of R-RPLND has been established with complication rates comparable to open RPLND and with decreased postoperative hospital stay and blood loss.SummaryAs R-RPLND continues to evolve and experience grows in high-volume centers, more information will be gained regarding long-term oncologic outcomes. Ultimately, head-to-head trials comparing R-RPLND to open RPLND will be needed to determine the role of R-RPLND in the treatment of testicular cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 173-179 |
| Number of pages | 7 |
| Journal | Current Opinion in Urology |
| Volume | 29 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2019 |
Keywords
- retroperitoneal lymph node dissection
- robotic surgery
- testicular cancer